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Abstract: Adenosine is a signalling molecule that modulates cellular activity in the central nervous system and peripheral 
organs via four G protein-coupled receptors designated A1, A2A, A2B, and A3. This review surveys the literature on the role 
of adenosine in auditory function, particularly cochlear function and its protection from oxidative stress. The specific 
tissue  distribution  of  adenosine  receptors  in  the  mammalian  cochlea  implicates  adenosine  signalling  in  sensory 
transduction and auditory neurotransmission although functional studies have demonstrated that adenosine stimulates co-
chlear  blood  flow,  but  does  not  alter  the  resting  and  sound-evoked  auditory  potentials.  An  interest  in  a  potential 
otoprotective  role  for  adenosine  has  recently  evolved,  fuelled  by  the  capacity  of  A1  adenosine  receptors  to  prevent 
cochlear injury caused by acoustic trauma and ototoxic drugs. The balance between A1 and A2A receptors is conceived as 
critical  for  cochlear  response  to  oxidative  stress,  which  is  an  underlying  mechanism  of  the  most  common  inner  ear 
pathologies  (e.g.  noise-induced  and  age-related  hearing  loss,  drug  ototoxicity).  Enzymes  involved  in  adenosine 
metabolism, adenosine kinase and adenosine deaminase, are also emerging as attractive targets for controlling oxidative 
stress in the cochlea. Other possible targets include ectonucleotidases that generate adenosine from extracellular ATP, and 
nucleoside transporters, which regulate adenosine concentrations on both sides of the plasma membrane. Developments of 
selective adenosine receptor agonists and antagonists that can cross the blood-cochlea barrier are bolstering efforts to 
develop therapeutic interventions aimed at ameliorating cochlear injury. Manipulations of the adenosine signalling system 
thus hold significant promise in the therapeutic management of oxidative stress in the cochlea. 
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INTRODUCTION 
  The cochlea of the auditory system is one of the master-
pieces of the human body. Its unique structure enables analy-
sis of complex sounds by translating them into bio-electrical 
messages delivered to the brain. Sound energy is collected 
and focused by the outer ear, and directed through the middle 
ear to the cochlea. Here the mechano-electrical transduction 
processes take place whereby sensory hair cells detect each 
frequency component of the stimulus and convert these into 
neural impulses which are transmitted to the brain. The com-
plex  auditory pathways from  the brainstem  through to  the 
auditory cortex enable analysis of the sound to provide in-
formation on aspects of the sound stimulus such as the local-
isation of sound sources, frequency discrimination, and de-
tection of complex patterns characteristic of speech. 
  Hearing is a key sense in human communication and the 
loss of hearing can be very socially debilitating. According 
to the World Health Organization (WHO), hearing loss is the 
6
th ranked cause of the global disease burden significantly 
affecting over 250 million people worldwide. Hearing loss 
from noise exposure (NIHL) is a leading occupational dis-
ease, with up to 5% of the population at risk. About 80% of 
the cases of hearing loss occur in people over the age of 50 
years and it is set to become a major disability as the popula-
tion ages with estimates of 26% of the population affected by 
2050 (Access Economics, 2006). Hearing loss may have a  
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major impact on the quality of life and psychological well-
being.  Communication  difficulties  and  poor  psychosocial 
functioning  may  lead  to  depression,  anxiety  and  possibly 
cognitive decline [35]. Even though acquired hearing loss is 
often preventable, finding safe and effective treatments for 
cochlear injury and subsequent hearing loss is a holy grail of 
auditory research. 
STRUCTURE OF THE INNER EAR 
  The  ear  is  divided  into  three  main  compartments,  the 
outer, the middle, and the inner ear, with the latter containing 
the balance (vestibular) and hearing (cochlea) organs.  The 
vestibular  part  of  the  inner  ear  comprises  the  sacculus, 
utriculus and the semi-circular canals, each containing one of 
the organs of balance. The cochlea  is  encased by  the otic 
capsule which spirals around the modiolus, a conical bony 
structure  (Fig.  1).  It  has  three  fluid-filled  compartments 
known  as  the  scala  vestibuli,  scala  media  (cochlear  duct), 
and scala tympani [22,82]. The scala vestibuli and scala me-
dia are separated by Reissner’s membrane, whereas the scala 
media and the scala tympani are separated by the organ of 
Corti and basilar membrane. The fluid within the scala vesti-
buli and scala tympani, known as perilymph, is a typical ex-
tracellular fluid, whereas the scala media is filled with potas-
sium-rich  endolymph,  an  intracellular-like  fluid.  Cochlear 
fluid homeostasis and generation of the endocochlear poten-
tial,  a  positive  electrical  potential  within  the  scala  media 
which is the main driving force for sensory transduction, are 
critical for normal cochlear function [116]. The stria vascu-
laris and spiral ligament, which comprise the lateral wall of 
the  scala  media,  are  actively  involved  in  these  processes 
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  Resting upon the basilar membrane is the organ of Corti, 
the sensory organ of hearing (Fig. 1). The organ of Corti is a 
highly differentiated sensory epithelium, consisting of spe-
cialised hair cells interdigitating with various types of sup-
porting cells [22,82]. Two types of hair cells exist – inner 
hair cells (IHCs), which are the primary sensory cells, and 
outer hair cells (OHCs) that enhance the sensitivity and fre-
quency selectivity of hearing through an electromotile proc-
ess. Occupying the apical surfaces of the hair cells are cellu-
lar projections known as stereocilia, and these are intercon-
nected by tip links and side links [22,82]. It is the stereocilia 
that mediate the transduction of complex sound waves into 
electrical  activity  in  the  auditory  nerve.  The  basilar  mem-
brane is a hydromechanical frequency analyser that encodes 
high frequency sound at the base and low frequency sound at 
the apex [21]. Movement of the basilar membrane results in 
bending of stereocilia on hair cells and opening of mechani-
cally-gated transduction ion channels [82]. Influx of potas-
sium ions from endolymph through these transduction chan-
nels depolarises the inner hair cells, which in turn activate 
voltage-gated calcium channels in the basal pole of the cell. 
Calcium entry triggers the release of glutamate, which gen-
erates  nerve  impulses  in  the  primary  auditory  neurons  lo-
cated  within  the  spiral  ganglion.  The  inner  hair  cells  thus 
perform  the  crucial  process  of  sensory  transduction  in  the 
cochlea that initiates the activity in the spiral ganglion affer-
ent neurones. 
PURINERGIC REGULATION OF HEARING 
  Extracellar purines such as adenosine and adenosine 5’-
triphosphate  (ATP)  are  intrinsically  related  molecules  that 
regulate a number of physiological processes in the auditory 
system, typically acting in a paracrine or autocrine manner. 
This purinergic signalling system is very sensitive to changes 
in the extracellular environment (e.g. due to noise, hypoxia, 
ischemia,  trauma) and promptly responds to them. Adeno-
sine and ATP appear to be important signalling molecules in 
pathological conditions, when the extracellular levels of both 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Mammalian cochlea. A) A cross section through the cochlea shows the central bony part (modiolus) which contains blood vessels 
and the auditory nerve, and the cochlear coiling divided into three compartments: scala vestibuli, scala media and scala tympani. Scala vesti-
buli and scala tympani contain perilymph. The organ of Corti (oc) sits on the basilar membrane and bathes in the potassium-rich fluid of the 
scala media (endolymph). B) Sensory tissues in the cochlea are located in the organ of Corti, secretory tissues is represented by the stria vas-
cularis (sv) and primary auditory neurons are located in the spiral ganglion. High potassium content of the endolymph is maintained by se-
cretion from the stria vascularis supported by the spiral ligament (sl). Afferent innervation of the inner and outer hair cells is provided by the 
spiral ganglion neurons (sgn). C) The organ of Corti comprises sensory cells (inner and outer hair cells) and a variety of supporting cells 
(Deiters’, Hensen’s and pillar cells). D) Surface preparation of the organ of Corti stained with phalloidin showing three rows of outer hair 
cells and one row of inner hair cells with the apically located stereocilia responsible for mechano-eletrical transduction. Abbreviations: IHC, 
inner hair cells; OHC, outer hair cells; rm, Reissner’s membrane; tm, tectorial membrane. 248    Current Neuropharmacology, 2009, Vol. 7, No. 3  Vlajkovic et al. 
are  elevated  in  the  cochlea.  This  review  will  highlight 
purinergic regulation of hearing function with an emphasis 
on the role of extracellular adenosine in the most common 
inner ear pathologies. 
ATP  SIGNALLING  IN  THE  COCHLEA  AND  HY-
DROLYTIC CONVERSION TO ADENOSINE  
  ATP can be released from cochlear tissues under stressor 
conditions  such  as  acoustic  overstimulation  [73],  with  re-
lease sites identified in the organ of Corti [115] and within 
vesicles in the marginal cells of the stria vascularis [73,117]. 
Connexin and pannexin hemichannels are likely to be princi-
pal conduits for ATP release [123]. ATP released from dam-
aged cells triggers Ca
2+ mobilization and a regenerative re-
lease of ATP from supporting cells [34]. During the early 
stages of cochlear development supporting cells of the organ 
of Corti also rhythmically release ATP to initiate spontane-
ous action potentials in the auditory nerve before the onset of 
hearing, pointing to their role in the development of central 
auditory pathways [103]. Released ATP acts on P2 receptors 
which also respond to other extracellular purines and pyri-
midines (ADP, UTP, UDP). ATP-gated ion channels (P2X 
receptors) and G protein-coupled P2Y receptors are differen-
tially distributed in cochlear tissues with distinctive roles in 
auditory  neurotransmission  [45],  sensory  transduction  [46] 
and the maintenance of cochlear homeostasis [14,58,101].  
  Endogenous  ATP  levels  in  cochlear  fluids  are  tightly 
controlled by ectonucleotidases [71,107]. Ectonucleotidases 
are  surface  located  enzymes  hydrolysing  extracellular  nu-
cleotides to their respective nucleosides. Several groups of 
enzymes are involved in ATP breakdown to adenosine, in-
cluding ectonucleoside triphosphate diphosphohydrolase (E-
NTPDase) family, ectonucleotide pyrophosphatase/phospho-
diesterase  family  (E-NPP)  and  alkaline  phosphatase  [87, 
124]. Principal hydrolytic enzymes in cochlear fluid spaces 
are  NTPDases  [109,110,112].  Surface-located  NTPDase1, 
NTPDase2,  NTPDase3  and  NTPDase8  have  a  capacity  to 
hydrolyse ATP to AMP [87]. Dephosphorylation of AMP to 
adenosine  by  ecto-5’-nucleotidase  (CD73)  represents  the 
final step of the ectonucleotidase cascade. Ectonucleotidases 
thus limit ATP and ADP spatio-temporal activity and con-
vert  the  P2 receptor into P1 (adenosine) receptor environ-
ment.  
ADENOSINE  RECEPTOR  EXPRESSION  AND  DIS-
TRIBUTION IN THE AUDITORY SYSTEM 
  A family of four adenosine receptors (A1, A2A, A2B, A3) 
is expressed in the rat cochlea [113]. These G protein-coupled 
receptors utilize different intracellular signalling pathways. 
The  classical  pathway  of  adenosine  signalling  is  through 
inhibition or stimulation of adenylyl cyclase, but other path-
ways  involving  intracellular Ca
2+ release, phospholipase  C 
(PLC), and mitogen-activated protein kinases (MAPK)  are 
also essential [48]. The A1 receptor and A3 receptor couple to 
Gi/o  proteins  that  inhibit  adenylyl  cyclase,  resulting  in  in-
creased activity of PLC. A2 receptors stimulate adenylyl cy-
lase via Gs or Golf proteins. Stimulation of the A2 receptors 
leads to formation of inositol phosphates to raise intracellular 
calcium and activate PKC via pertussis toxin-sensitive Gα15 
and Gα16 [74]. Adenosine A3 receptor stimulation directly 
activates  PI3  kinase  as  demonstrated  by  dose-dependent 
phosphorylation of PKB/Akt which is a downstream target 
of PI3 kinase [48]. Activation of PKB may be an underlying 
mechanism of anti-apoptotic activity of A3 receptors, due to 
direct  phosphorylation  and  inhibition  of  the  Bcl-2  family 
member BAD [54].  
  All four adenosine receptors couple to ERK1/2  MAPK 
[48], whilst A2B and A3 receptors can also activate JNK and 
p38 [29,39]. MAPK signalling represents an important path-
way  for  G  protein-coupled  receptors  to  modify  gene  tran-
scription of a series of transcription factors [67]. Stress-acti-
vated pathways contribute to pathophysiological responses to 
stress and apoptosis of ROS-damaged cells [38]. In the coch-
lea, JNK inhibition protects against hair cell death and hear-
ing  loss  induced  by  acoustic  trauma  and  aminoglycoside 
antibiotics [114].  
  High affinity adenosine receptors (A1, A2A, A3) are dif-
ferentially localised in cochlear tissues [113]. A1R is distrib-
uted  in  the  organ  of  Corti  and  spiral  ganglion  neurons. 
Within the organ of Corti, A1R are expressed predominantly 
in the supporting Deiters’ cells and the inner hair cells (IHC). 
A2A receptors are localised to the organ of Corti, spiral gan-
glion neurons, root region of the spiral ligament and the co-
chlear blood vessels. The A3 receptor is predominantly ex-
pressed in the inner and outer hair cells and supporting cells 
of  the  organ  of  Corti,  including  the  Deiters’,  Hensen’s, 
Claudius and pillar cells, as well as the epithelial cells lining 
the endolymphatic fluid space (inner and outer sulcus cells) 
and interdental cells of the spiral limbus. Cell bodies of the 
spiral ganglion neurons also exhibit strong A3R-specific im-
munoreactivity [113].  
  On the basis of immunohistochemistry there is good evi-
dence that the inner hair cells, supporting Deiters’ cells and 
spiral ganglion neurons are the dominant cells which express 
multiple adenosine receptors (Table 1). The localization of 
adenosine receptors in these cellular regions, which are im-
portant  for  sound  transduction,  auditory  neurotransmission 
and cochlear micromechanics, implicates adenosine signal-
ling in the modulation of sound detection and hearing sensi-
tivity. The expression of A1, A2A and A3 receptors by inner 
hair cells is consistent with adenosine-induced elevation of 
intracellular Ca
2+ in these cells of the guinea-pig [23]. A1 and 
A3 receptors have also been suggested to have an important 
role in presynaptic regulation of glutamate release from the 
inner hair cells, consistent with their role in modulating glu-
tamate release in brain neurones [17,18]. 
  The cell bodies of the spiral ganglion neurones express 
A1,  A2A  and  A3  receptors  which  may  fulfil  different  roles 
according to the level of activation. The main role of adeno-
sine  in other  tissues is  to inhibit neuronal  excitability and 
synaptic transmission, acting predominantly on A1 receptors 
[24]. A3 receptors may also have a role in synaptic transmis-
sion  similar  to  A1  receptors  [10,16],  whilst  A2A  receptors 
facilitate  the  release  of  excitatory  neurotransmitters  [17]. 
However, although these adenosine receptors are expressed 
in spiral ganglion neurones their functional role in these cells 
is still to be determined.  
  Adenosine receptors have also been identified in parts of 
the central auditory nervous system. A1 adenosine receptors 
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complex, inferior colliculus, and auditory cortex in the tem-
poral lobe [86]. In most of these regions, A1 receptors are 
located on cell bodies and axons, supporting the concept that 
A1 receptors act both pre- and post-synaptically. A1 receptors 
are  heavily  distributed  in  regions  rich  in  excitatory  amino 
acids, implying that A1 receptor stimulation modulates exci-
tatory neurotransmission. In contrast to the A1 receptors, the 
distribution of A2A receptors in the central nervous system 
appears to be more discretely localised to parts of the inferior 
colliculus and layer VI of the auditory cortex [88].  
ADENOSINE METABOLISM IN THE COCHLEA 
  The sources of adenosine in cochlear tissues include nu-
cleoside  transport  from  the  intracellular  compartment,  ex-
tracellular nucleotide hydrolysis and release from damaged 
cells  [53,113].  Extracellular  adenosine  levels  are  dynami-
cally  regulated  by  the  release  and  reuptake  of  adenosine 
across the cell membrane via nucleoside transporters which 
have been identified in cochlear tissues [53]. Another poten-
tial source of adenosine is the activity of ectonucleotidases 
that  breakdown  extracellular  ATP  to  adenosine  [108-110]. 
Noise stress triggers the hydrolysis of ATP and generation of 
AMP, which is further dephosphorylated into adenosine by 
ecto-5’-nucleotidase [111]. Released adenosine is hydrolysed 
or removed from the extracellular space by nucleoside trans-
porters  [53].  Intracellularly,  adenosine  is  hydrolysed  by 
adenosine  deaminase  to  inosine,  whilst  adenosine  kinase 
(ADK), catalyses intracellular phosphorylation of adenosine 
to AMP. Based on its low KM for adenosine, ADK is likely a 
major regulator of ambient adenosine levels in the extracel-
lular space (Fig. 2).  
  The extracellular concentrations of adenosine in cells and 
tissue fluids are quite low under physiological conditions (in 
the nanomolar range), whereas in different forms of cellular 
distress  adenosine  levels  can  reach  as  high  as  100  µM 
[31,41]. In comparison, levels of intracellular ATP are 5-10 
mM under physiological conditions. Because the intracellu-
lar  concentration  of  ATP  is  so  much  higher  than  that  of 
adenosine, slight changes in ATP concentration will result in 
substantial changes in adenosine levels [18,30]. Damage to 
cell  membranes  during  trauma  causes  massive  release  of 
ATP into extracellular spaces and adenosine generation after 
ATP dephosphorylation by membrane-bound NTPDases and 
ecto-5’-nucleotidase  [111,112].  Both  purines  may  have  an 
otoprotective role under different stress conditions [59]. 
ADENOSINE TRANSPORT IN THE COCHLEA 
  Nucleoside transport appears to be essential for the regu-
lation of adenosine concentrations in the cochlear fluids [53] 
where  it is available to  influence cell function through its 
action on adenosine receptors. In most tissues, principal nu-
cleoside transport is mediated by equilibrative bidirectional 
transporters,  with  the  net  direction  of  transport  being  de-
pendent upon the concentration gradient of adenosine across 
the cell membrane [4]. Because these transporters equilibrate 
the levels of intracellular and extracellular adenosine, changes 
in the level on one side can alter the level on the opposite 
side  of  the  membrane.  The  equilibrative  nucleoside  trans- 
 
Table 1.  Overview of Adenosine Receptor Tissue Distribution in the Rat Cochlea 
  A1R  A2AR  A3R 
Organ of Corti       
     Inner hair cells  ++  ++  + 
     Outer hair cells      + 
     Deiters’ cells  ++  ++  ++ 
     Pillar cells      ++ 
     Hensen cells      + 
     Claudius cells      + 
Epithelial cells       
     Innner sulcus cells      ++ 
     Outer sulcus cells      ++ 
Lateral wall       
     Spiral ligament    ++  + 
     Stria vascularis       
Spiral ganglion neurones  +  ++  ++ 
Blood vessels    ++   
(+, light immunostaining; ++, strong immunostaining). 250    Current Neuropharmacology, 2009, Vol. 7, No. 3  Vlajkovic et al. 
porter (ENT) family has four members (ENT1-4). ENT1 and 
ENT2 show differential sensitivity to nitrobenzylthioinosine 
(NBMPR). NBMPR-sensitive ENT1 and NBMPR-insensitive 
ENT2 have broad substrate specificity and tissue distribution 
[5,55],  whilst  ENT3  and  ENT4  have  unknown  function. 
There is also a group of concentrative nucleoside transport-
ers (CNTs) that transport adenosine against the concentration 
gradient  [4].  In  contrast  to  facilitated  carrier  proteins,  the 
CNTs are Na
+-dependent uphill transporters. Na
+-dependent 
CNTs require energy from Na
+-K
+-ATPase to transport sub-
strates into cells against their concentration gradient. CNT1 
prefers  pyrimidine  nucleosides,  CNT2  purine  nucleosides 
and CNT3 transports both pyrimidine and purine nucleosides 
[37].  At  least  four  types  of  nucleoside  transporter  are  ex-
pressed in the cochlea [53] including two equilibrative trans-
porters (ENT1 and ENT2) and two concentrative transporters 
(CNT1 and CNT2) encoded by the gene families SLC28 and 
SLC29,  respectively.  Adenosine  uptake  studies  show  that 
adenosine transport in the cochlea represents the net activity 
of  Na
+-dependent  CNTs  and  Na
+-independent  ENTs  [53]. 
The  equilibrative  carriers  acting  via  facilitative  diffusion 
enable an intracellular influx of adenosine based on its con-
centration  gradient.  In  contrast,  concentrative  (uphill)  nu-
cleoside  transporters  counter  gradient-dependent  adenosine 
uptake  by  releasing  adenosine  from  the  tissue,  and  this  is 
likely a modus operandi during cellular distress. In addition 
to regulating the actions of adenosine at P1 receptors, adeno-
sine  reuptake  enables  purine  salvage  in  the  cochlea  and 
serves the maintenance of purinergic homeostasis. 
ADENOSINE  RECEPTORS,  COCHLEAR  BLOOD 
FLOW AND SOUND-EVOKED POTENTIALS 
  Perilymphatic perfusion of adenosine (1 µM - 10 mM) in 
the guinea-pig cochlea induces a dose dependent increase in 
cochlear blood flow [72]. The blood flow response to adeno-
sine is abolished in the presence of theophylline, a broadly 
specific  adenosine  receptor  antagonist  [72].  This  effect  of 
adenosine on cochlear blood flow is likely mediated by A2A 
receptors based on their distribution in cochlear blood ves-
sels [113]. The control of cochlear blood flow is important as 
compromised blood flow during chronic noise exposure and 
aging may lead to reduced auditory sensitivity [70,94].  
  Application of adenosine to isolated guinea-pig inner hair 
cells produces a small rise in intracellular Ca
2+ [23]. How-
ever, auditory potentials in the intact animal are seemingly 
not affected by adenosine receptor agonists. The non-hydro-
lysable adenosine analogue R-phenylisopropyladenosine (R-
PIA) applied on to the round window membrane does not 
affect  the  endocochlear potential which drives  the sensory 
transduction and has no influence on sound evoked auditory 
thresholds (e.g. auditory brainstem responses and compound 
action potential) [27]. Likewise, endolymphatic microinjec-
tions of adenosine (100 µM – 1 mM) in the guinea-pig coch-
lea do not change endocochlear potential and cochlear mi-
crophonic [73]. These data suggest that adenosine has lim-
ited effects on normal cochlear function, but further studies 
are required to identify cochlear responses to more selective 
adenosine receptor agonists than are currently available. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Adenosine production, transport and metabolism. 
The principal source of adenosine in extracellular fluid spaces is equilibrative nucleoside transport, with the net direction of transport being 
dependent upon the concentration gradient of adenosine across the cell membrane. Another source of adenosine is the activity of ectonucleo-
tidases that breakdown extracellular ATP to adenosine. Intracellular adenosine is formed from S-adenosyl homocysteine via SAH hydrolase 
(pathway not shown). Enzymes  contributing to  the hydrolytic cascade  that  converts ATP  to adenosine include NTPDases  and ecto-5’-
nucleotidase. Adenosine produced by extracellular ATP hydrolysis or transported from the intracellular compartment acts on adenosine re-
ceptors on target cells in a paracrine or autocrine fashion. Clearance of adenosine from the extracellular space is provided by nucleoside 
transporters.  Intracellular  adenosine  is  hydrolysed  by  adenosine  deaminase  to  inosine,  or  phosphorylated  to  AMP  by  adenosine  kinase 
(ADK), which appears to be a major regulator of ambient adenosine levels. Adenosine and the Auditory System  Current Neuropharmacology, 2009, Vol. 7, No. 3    251 
  Even  though  adenosine  receptor  stimulation  does  not 
affect auditory potentials, a role of adenosine signalling in 
cochlear protection from oxidative stress has received a con-
siderable  attention  in  recent  years.  The  next  section  will 
highlight  the  attempts  to  prevent  cochlear  injury  by  using 
selective agonists of adenosine receptors. 
NOISE  STRESS  AND  OTOPROTECTION  BY 
ADENOSINE 
  Adenosine receptor agonists have been successfully used 
in the treatment of ischemic brain and cardiac injury and are 
proving  to  have  extraordinary  cytoprotective  functions.  In 
the  central nervous system, purinergic mechanisms are in-
volved in various pathological conditions, including stroke, 
epilepsy, migraine, neurodegenerative and neuropsychiatric 
diseases [12,48]. The extensive background of neuroprotec-
tive action suggests that adenosine may also confer protec-
tion from noise-induced hearing loss, which has underlying 
mechanisms similar to some CNS pathologies.  
  There is increasing evidence that oxidative stress and the 
production  of  reactive  oxygen  species  (ROS)  are  key  ele-
ments in the pathogenesis of many forms of cochlear injury, 
for example from noise exposure, cytotoxic drugs and with 
aging. Indeed oxidative  stress,  along with neurotoxicity of 
glutamate, is being viewed almost as a unifying mechanism 
underlying  most  cochlear  damage  and  hearing  loss.  Thus 
compounds  that  target  mechanisms  underlying  oxidative 
stress  offer  considerable  potential  as  therapies  for  hearing 
loss.  
  Noise exposure is a major cause of injury to the cochlea 
and hearing loss. It can be caused by an acute exposure to 
loud  sound  as  well  as  by  repeated  exposure  to  moderate 
sounds over an extended period of time. Explosions and im-
pulsive sounds can result in immediate hearing loss, whilst 
continuous  exposure  to  loud  noise,  as  experienced  in  the 
workplace or with recreational activities, likely damages the 
cochlea by slower metabolic mechanisms. Chronic exposure 
to high levels of noise can cause damage to the sensitive hair 
cells of the inner ear as well as the auditory nerve. Exposure 
to impulse or continuous noise may cause permanent or tem-
porary  hearing  loss.  The  term  ‘temporary  threshold  shift’ 
(TTS) has been used to indicate a transient impairment of 
auditory function due to noise trauma, and it usually disap-
pears within few days after exposure to loud noise. Perma-
nent threshold shift (PTS) occurs when post-exposure hear-
ing thresholds have been stabilized at elevated levels.  
  Noise  exposure  drives  mitochondrial  activity  and  free 
radical production, reduces cochlear blood flow, causes exci-
totoxic swelling of afferent nerve terminals, and induces both 
necrotic and apoptotic cell death in the organ of Corti [42]. 
The formation of reactive oxygen species (ROS) results from 
increased  mitochondrial  activity  [77].  ROS  are  molecules, 
ions and free radicals such as the superoxide ion, hydrogen 
peroxide, peroxynitrite, and hydroxyl radical. Under normal 
conditions,  ROS  produced  by  the  mitochondria  are  easily 
metabolized or scavenged by endogenous antioxidant mecha-
nisms. However, in the presence of excess ROS, the intrinsic 
cochlear defenses may be insufficient to control ROS pro-
duction. ROS are formed as by-products of several metabolic 
pathways and these molecules can cause damage by reacting 
with DNA, proteins, membrane  lipids, cytosolic  molecules 
and  cell  surface  receptors.  The  common  ROS-initiating 
events are alterations of intracellular Ca
2+ homeostasis and 
glutamate excitotoxicity [56]. NADPH oxidase may have a 
pivotal  role  in  ROS  formation  in  the  cochlea  induced  by 
noise  exposure  [81].  ROS-induced  changes  in  the  cochlea 
include lipid peroxidation with the formation of malondial-
dehyde and 4-hydroxynonenal (4-HNE), inactivation of anti-
oxidant enzymes and depletion of glutathione [83], leading 
to abnormalities in cochlear function [15]. Lipid peroxida-
tion provides a link between the initial biochemical events in 
noise trauma and downstream intracellular pathways leading 
to  apoptotic  cell  death.  The  generation  of  lipid  peroxides 
appears to be highly correlated with pathophysiological find-
ings in the noise-exposed cochlea [76].  
  Cells protect themselves against oxidative stress via an 
antioxidant  defense  system  that  maintains  the  appropriate 
redox state of cellular proteins. Antioxidant defenses can be 
augmented by a variety of molecules, including ROS scav-
engers (superoxide dismutase, catalase and glutathione per-
oxidase), trophic factors, protease inhibitors, lipid peroxida-
tion inhibitors, heat shock proteins, and inhibitors of apopto-
sis [3,56,75,76]. 
  Released  adenosine  may  account  for  anti-oxidative  de-
fense  and  regeneration  in  a  range  of  tissues  [31,48,62]. 
Adenosine release in the cochlear fluid spaces is stimulated 
by  oxidative  stress  [8]  and  by  the  activation  of  excitatory 
neurotransmission via NMDA receptors [92] densely distrib-
uted  at  the  IHC  afferent  nerve  endings.  Ectonucleotidases 
NTPDase1, NTPDase2 and NTPDase3 are up-regulated dur-
ing  noise  exposure,  generating  more  adenosine  from  ATP 
hydrolysis by coupling to ecto-5’-nucleotidase [111,112]. In 
addition,  οxidative stress upregulates  the A1 adenosine re-
ceptor expression in the chinchilla cochlea via activation of 
NF-κΒ [51,81], whilst nitric oxide serves as an endogenous 
regulator of A1 receptors [50]. Round window application of 
the A1 receptor agonist R-PIA in chinchilla cochlea enhances 
activity of the two principal antioxidant enzymes in the coch-
lea,  superoxide  dismutase  and  glutathione  peroxidase  and 
reduces the levels of malondialdehyde, a marker of lipid per-
oxidation [27]. The pretreatment of the cochlea with R-PIA 
attenuates noise-induced hearing loss in animals exposed to a 
4 kHz octave band noise (105 dB SPL for 4h) [47]. The re-
duction of permanent threshold shift is associated with re-
duced outer hair cell loss in R-PIA treated ears, suggesting 
that A1 receptors facilitate the recovery process of the outer 
hair cells after noise exposure. In addition, the combination 
of  R-PIA  with  the  antioxidant  glutathione  monoethylester 
provides otoprotection against both impulse and continuous 
noise in the chinchilla cochlea [43]. These findings support 
the otoprotective role of adenosine A1 receptors which have 
the capacity to increase the production of antioxidants and 
counter the toxic effects of ROS and glutamate [43,47,81]. 
CISPLATIN OTOTOXICITY AND ADENOSINE  
  Pharmacological targeting of A1 receptors is a novel ap-
proach to the prevention and treatment of ototoxicity. Two 
major classes of therapeutic agents can induce acquired hear-
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motherapy agents [90]. These drugs target the outer hair cells 
particularly in the basal region of the cochlea to cause high 
frequency  sensorineural  hearing  loss.  Generation  of  ROS 
appears to be  the principal mechanism of ototoxicity [91], 
triggering downstream cell death signalling pathways. Cis-
platin is widely used to treat malignancies ranging from tes-
ticular, ovarian and bladder cancers to lung, head and neck 
malignancies. Audiometric measurements indicate that most 
patients develop at least some degree of hearing loss [91]. 
Elderly patients and children under 5 years of age are par-
ticularly  susceptible  to  cisplatin  ototoxicity  [61].  Cisplatin 
affects  sensory  hair  cells  involved  in  sound  transduction, 
spiral ganglion cells involved in auditory neurotransmission, 
and the lateral wall tissues (spiral ligament and stria vascu-
laris) involved in K
+ secretion and cycling. Cisplatin induces 
ROS generation in cochlear tissues and upregulation of the 
NOX3  isoform  of  NADPH  oxidase  [6].  This  leads  to  in-
creased production of superoxide ions, followed by forma-
tion of more toxic hydroxyl radical that interacts with poly-
unsaturated fatty acids in the cell membrane to form toxic 
aldehyde 4-hydroxynonenal (4-HNE). In addition, superox-
ide can react with nitric oxide to generate peroxynitrite radi-
cal which reacts with cell membrane proteins to form nitroty-
rosine (NT). NT and 4-HNE are frequently used markers of 
free radical damage in the cochlea [52,121]. 
  Even though the cochlea has endogenous mechanisms to 
deal with oxidative stress, these can be overwhelmed by ex-
cessive ROS production induced by cisplatin. In experimen-
tal conditions, cisplatin ototoxicity can be prevented by ROS 
scavengers  (e.g.  ebselen  and  N-acetylcysteine),  neurotro-
phine-3, inhibitors of caspase 3 and 9, p53 inhibitor [89,91]. 
However, there is a concern that these drugs can interfere 
with the anti-tumor activity of cisplatin [7], hence alternative 
approaches have been sought. It has been shown that sys-
temic sodium salicylate [60], or combination of ebselen and 
allopurinol [64,65] can protect against cisplatin ototoxicity 
without altering its antineoplastic activity.  
  Cisplatin treatment induces a fivefold increase in A1 re-
ceptor expression in the cochlea under experimental condi-
tions [28], and the local application of adenosine A1 receptor 
agonists R-PIA or 2-chloro-N6-cyclopentyladenosine (CCPA) 
onto  the  round  window  membrane  of  the  cochlea  reduces 
cisplatin-induced auditory threshold shifts [118]. Protective 
effects can be reversed by pre-administration of the A1 recep-
tor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX). 
Despite encouraging initial data about the protective effects 
of adenosine receptor agonists on cisplatin ototoxicicty, fur-
ther studies are required to demonstrate that systemic appli-
cation  of  selective  A1  receptor  agonists  does  not  interfere 
with anti-cancer effects of cisplatin. 
AGING AND OTOPROTECTION BY ADENOSINE 
  The  term  presbyacusis  encompasses  all  conditions  that 
lead to hearing loss in elderly people. The disorder is charac-
terised by reduced hearing sensitivity and speech understand-
ing  in  noisy  environments,  slowed  central  processing  of 
acoustic  information,  and  impaired  localisation  of  sound 
sources [35]. The mechanisms of age-related hearing loss are 
poorly  understood,  but  there  is  evidence  that  both  genetic  
 
and environmental factors play a role. Presbyacusis can be 
regarded as a mixture of acquired auditory stresses, trauma, 
and  otological  diseases  superimposed  upon  a  genetically 
controlled  aging  process  [35].  Some  people  and  animal 
strains show greater resistance to hearing loss, which may 
reflect differences in their response to stressors such as noise 
exposure.  
  A number of mechanisms have been proposed to explain 
age-related  cochlear  injury.  A  dominant  theory  is  that  the 
damage arises from production of ROS [93], possibly as a 
consequence of impaired blood flow [20] or environmental 
factors such as excessive noise exposure [96]. This leads to 
membrane  damage  and  damage  to  mitochondrial  DNA 
[26,80,95,105].  Increased  prevalence  of  apoptosis  in  co-
chlear hair cells in aged mice [106] and Mongolian gerbil [2] 
suggests that hair cell death is associated with activation of 
apoptotic pathways.  
  In the central nervous system, pathologies that respond 
well to adenosine drugs (e.g. Parkinson’s and Alzhemier’s 
disease, ischemic conditions and sleep disorders) are preva-
lent in elderly. In aged animals, expression levels and density 
of A1 adenosine receptors decrease  in some brain regions, 
whilst  the  density  of  A2A  adenosine  receptor  increases 
(17,18,63,84]. The metabolism of adenosine is also altered in 
the  aging  brain  [18],  implicating  dysfunctional  adenosine 
homeostasis. Similarly, adenosine signalling and adenosine 
metabolism are altered in the heart of older animals leading 
to  reduced  capacity  for  cardioprotection  [119].  Assuming 
that expression levels and density of adenosine receptors in 
the aging cochlea may undergo comparable changes, restor-
ing the youthful balance of adenosine signalling by molecu-
lar and pharmacological means has a potential to diminish 
the progress of age-related hearing loss. 
ADENOSINE  AS  AN  ANTI-INFLAMMATORY 
AGENT IN THE COCHLEA  
  Sensorineural hearing loss and balance disorders are well 
known complications of meningitis [69] and otitis media, the 
prominent ear pathology of young children [13,78]. Middle 
ear  infections  can  induce  the  inflammation  of  inner  ear 
tissues by spread of toxins and bacteria through the round 
window  membrane  [19]  whilst  the  meningeal  infection 
spreads through the cochlear aqueduct, modiolus or hemato-
genically [19,69]. Labyrinthitis, or inflammation of the inner 
ear, can be caused by bacteria or viruses and is characterised 
by infiltration of inflammatory cells and damage to the inner 
ear tissues [78]. Environmental insults such as noise trauma 
can also cause an inflammatory response by the production 
of pro-inflammatory cytokines [32], which may exacerbate 
or  induce  further  cochlear  injury  through  a  number  of 
mechanisms, including metabolic pathways that involve oxi-
dative stress [42]. A cochlear inflammatory response initiated 
in response to acoustic trauma involves the recruitment of 
circulating  leukocytes  to  the  inner  ear  [40,44,102].  While 
macrophages  and  other  leukocytes  may  contribute  to c o-
chlear repair, the production of pro-inflammatory cytokines 
is also important in cochlear injury [32]. Similar mechanisms 
likely also contribute to the pathophysiology of age-related 
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  During metabolic stress in other tissues, released adeno-
sine limits excessive infiltration of neutrophils and mononu-
clear phagocytes and the release of pro-inflammatory cytoki-
nes [25]. Even though cells involved in immune and inflam-
matory responses (T cells, macrophages, dendritic cells) ex-
press all four adenosine receptor subtypes (A1, A2A, A2B, A3) 
[9], the A2A receptor has been singled out as the principal 
modulator of inflammatory responses [57,68,98]. A1 recep-
tors on macrophages also play a protective role in inflamma-
tion [99,104], in addition to their role in tissue protection and 
regeneration [30,31,62].  
  In some instances, inflammatory responses become dele-
terious [66] and require anti-inflammatory treatment. Current 
treatments of cochlear inflammation are based on steroids, 
which have positive short-term effects. However, long term 
steroid treatment is known to have a negative effect and can 
be  pro-inflammatory.  Adenosine-based  treatment  strategies 
based on the anti-inflammatory potential of A2A adenosine 
receptors could represent powerful tool in limiting cochlear 
inflammation and consequent hearing loss.  
PUTATIVE  MECHANISMS  OF  OTOPROTECTION 
BY ADENOSINE 
  A  number  of  studies  have  demonstrated  that  cochlear 
injury caused by noise exposure and ototoxic drugs can be 
prevented or reduced by drugs targeting A1 adenosine recep-
tors. Adenosine mechanisms accounting for tissue protection 
are numerous. They improve cochlear blood flow and oxy-
gen  supply,  increase  the  production  of  antioxidants,  and 
counter  the  toxic  effects  of  ROS  [31,62].  Adenosine  can 
limit inflammatory responses [25,30] and provide vascular 
growth  in  areas  with  reduced  oxygen  tension  [1].  Angio-
genesis may be important in cochlear repair after injury and 
angiogenic  factors  such  as  adenosine  may  be  useful  in 
therapy of chronic inner ear pathologies. 
  Other mechanisms underlying adenosine receptor-medi-
ated cytoprotection includes inhibition of glutamate release 
via presynaptic A1 receptors [30]. Activation of the presyn-
aptic A1 receptors reduces Ca
2+ influx through the preferen-
tial inhibition of N-type and Q-type channels [120,122]. The 
postsynaptic effects of A1 receptors include direct hyperpo-
larisation of neurones via G protein-activated inwardly recti-
fying K
+ channels Kir 3.2 and 3.4 [100]. These mechanisms 
may lead to reduced cochlear sensitivity in the time of stress. 
In contrast, selective stimulation of adenosine A2A receptors 
increases excitatory amino acid release [17] and may con-
tribute to cochlear injury.  
  To date, the role of adenosine receptors in mediating the 
cochlear response to stress and their therapeutic potential are 
still  vague.  Stimulation  of  A1  receptors  can  prevent  acute 
onset  inner  ear  pathologies,  but  prolonged  activation  can 
cause  receptor  desensitisation  and  down-regulation  which 
can hamper their neuroprotective potential in chronic condi-
tions [18]. Translation research using A1 receptor agonists to 
provide  otoprotection  and  neuroprotection  has  been  con-
founded by their profound cardiovascular effects (bradycar-
dia, hypotensia and hypothermia) and poor blood-brain bar-
rier permeability upon systemic administration [11,97]. On 
the bright side, selective A1 adenosine receptor agonists have 
been developed with reduced peripheral side effects and in-
creased ability to cross the blood-brain barrier [49]. Some of 
these adenosine receptor prodrugs hold promise for systemic 
interventions in the inner ear pathologies. 
  A2A and A3 receptors have a different role in cochlear 
response to oxidative stress. The stimulation of A2A receptors 
aggravates drug-induced cochlear injury [118], suggesting an 
inhibition of A2A adenosine receptors as attractive strategy 
for therapeutic management of chronic inner ear conditions. 
As  for  the  A3  receptors  agonists,  they  have  a  potential  to 
promote tissue survival at lower concentrations [27], but may 
induce apoptosis at higher concentrations [33], making them 
less viable therapeutic options. 
CONCLUSION AND FUTURE STRATEGIES 
  Currently there are very few interventions for sensorineu-
ral hearing loss, apart from hearing aids which do not restore 
normal hearing. Hearing conservation programmes to reduce 
hearing loss from noise exposure have been only marginally 
successful. Thus the search for new treatments and interven-
tions is essential to reduce the incidence and impact of the 
hearing  disability.  Extracellular  adenosine,  acting  via  P1 
receptors,  provides  a  primary  signal  transduction  pathway 
that  could  be  used  to  affect  the  progression  of  cochlear 
stress-induced pathology. The distribution of adenosine re-
ceptors in sensory and neural tissues of the cochlea, A1 re-
ceptor  up-regulation  during  noise  exposure,  and  reduced 
noise-induced  cochlear  injury  after  pretreatment  with  A1 
receptor agonists suggest that adenosine receptors are well 
positioned to provide  cochlear protection from loud sound 
and promote recovery from noise exposure and other forms 
of oxidative stress. Multiple cytoprotective actions of adeno-
sine in other tissues suggest that it has the potential to coun-
teract  the  effect  of  oxidative  stress  which  is  the  basis  of 
many forms of cochlear injury that cause hearing loss.  
  In addition to A1 receptor associated pathways, potential 
adenosine based otoprotective strategies include: 
•  Combined Inhibition of A2A Receptors and Adenosine 
Kinase 
  Coupling A2A receptor and adenosine kinase inhibition, 
which  increases  endogenous  adenosine  levels,  may  be  the 
most  robust  neuroprotective  strategy  based  on  adenosine 
signalling  system  [18].  The  inhibition  of  adenosine  kinase 
and A2A receptors can be effective over a long period of time 
without apparent side effects [36], and may be particularly 
effective in elderly [18]. 
•  Inhibition of Adenosine Uptake by Nucleoside Trans-
porters 
  The selective inhibition of adenosine uptake may prove 
clinically relevant in cochlear protection, as it may serve to 
increase extracellular adenosine concentrations [53].  
•  Increasing Adenosine Production from ATP  
  The up-regulation of ectonucleotidase activity in cochlear 
fluid spaces serves not only to limit ATP signalling, but also 
to increase adenosine production and consequently cochlear 
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•  Manipulating Adenosine Metabolism  
  Adenosine kinase and adenosine deaminase are the prin-
cipal  enzymes  involved  in  regulation  of  intracellular  and 
extracellular adenosine levels and their inhibition may have a 
potential  to  ameliorate  noise-induced  cochlear  injury  and 
restore hearing. 
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